Serum GFAP as a biomarker for disease severity in multiple sclerosis

While neurofilament light chain (NfL) measurement in serum is a well-established marker of neuroaxonal damage in multiple sclerosis (MS), data on astroglial markers in serum are missing. In our study, glial fibrillary acid protein (GFAP) and NfL were measured in cerebrospinal fluid (CSF) and serum o...

Celý popis

Uložené v:
Podrobná bibliografia
Vydané v:Scientific reports Ročník 8; číslo 1; s. 14798 - 7
Hlavní autori: Abdelhak, A., Huss, A., Kassubek, J., Tumani, H., Otto, M.
Médium: Journal Article
Jazyk:English
Vydavateľské údaje: London Nature Publishing Group UK 04.10.2018
Nature Publishing Group
Nature Portfolio
Predmet:
692/617/375/1666
692/617/375/365
Autoimmune diseases
Cerebrospinal fluid
Expanded Disability Status Scale (EDSS)
GFAP Levels
Glial fibrillary acidic protein
Glial Fibrillary Acidic Protein (GFAP)
Humanities and Social Sciences
Lesions
Magnetic resonance imaging
multidisciplinary
Multiple sclerosis
Neurological diseases
Relapsing-remitting MS (RRMS)
Science
Science (multidisciplinary)
Serum GFAP
Serum levels
Relapsing-remitting MS (RRMS)
Glial Fibrillary Acidic Protein (GFAP)
Expanded Disability Status Scale (EDSS)
Serum GFAP
GFAP Levels
ISSN:2045-2322, 2045-2322
On-line prístup:Získať plný text
Tagy: Pridať tag
Žiadne tagy, Buďte prvý, kto otaguje tento záznam!
Popis
Shrnutí:While neurofilament light chain (NfL) measurement in serum is a well-established marker of neuroaxonal damage in multiple sclerosis (MS), data on astroglial markers in serum are missing. In our study, glial fibrillary acid protein (GFAP) and NfL were measured in cerebrospinal fluid (CSF) and serum of MS patients and patients with other non-inflammatory neurological diseases (OND) using the Simoa technology. Clinical data like age, gender, expanded disability status scale (EDSS) and MRI findings were correlated to neurochemical markers. We included 80 MS patients: 42 relapsing-remitting MS (RRMS), 38 progressive MS (PMS), as well as 20 OND. Serum GFAP levels were higher in PMS compared to RRMS and OND (p < 0.001, p = 0.02 respectively). Serum GFAP levels correlated with disease severity in the whole MS group and PMS (Spearman-rho = 0.5, p < 0.001 in both groups). Serum GFAP correlated with serum NfL in PMS patients (Spearman-rho = 0.4, p = 0.01). Levels of serum GFAP were higher with increasing MRI-lesion count (p = 0.01). in summary, we report elevated levels of GFAP in the serum of MS patients. Since serum levels of GFAP correlate with the clinical severity scores and MRI lesion count, especially in PMS patients, it might be a suitable disease progression marker.
Bibliografia:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 14
content type line 23
ISSN:2045-2322
2045-2322
DOI:10.1038/s41598-018-33158-8